Abstract

The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center (CCC) has a long history of participation within the nation's cancer related Clinical Trials Cooperative Group Program. Specifically, UAB was a founding member of the GOG, and has been a member of RTOG, ECOG, ACRIN. CALGB, NSABP, and SWOG. The UAB CCC now submits this proposal to become a Lead Academic Participating Site, specifically named the NCTN Deep South Research Consortium, in the NCI's newly restructured National Clinical Trials Network (NCTN) Program. It is our intention to continue as a leading contributor of scientific leaders and clinical trial participants to the NCTN Program in th U.S. and particularly in the Southeast. To accomplish this overall vision, we propose the following specific aims: 1) To further enhance the involvement of existing UAB CCC scientific leadership in NCTN Center related clinical and translational research and to develop the next generation of NCTN Center scientific leaders within the UAB CCC, and 2) To further refine a clinical trials process within the UAB CCC that optimizes accrual of potentially eligible cancer patients and patients at risk for cancer to NCTN Center clinical trials. We include in this proposa a detailed description of our NCI cooperative group scientific and patient accrual contributions and accomplishments, a leadership and organizational structure for our proposed Consortium, and how we intend to utilize existing UAB CCC infrastructure to achieve our aims. We also include a detailed description of our proposed Junior Investigator Recruitment and Mentoring Program.

Public Health Relevance

This proposal will ensure that the NCTN Program is provided better access to UAB CCC clinical and translational investigators with a broad interest in cancer prevention and control, cancer biology, and experimental therapeutics. Importantly, this proposal will also provide NCTN clinical trials better access to a patient population that based upon its demographics and socioeconomic status is distinct from other areas in the country.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180855-05
Application #
9439700
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-16
Project End
2019-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
University of Alabama Birmingham
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294

  Publications

Barrington, David A; Champion, Macie L; Boitano, Teresa K L et al. (2018) Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecol Oncol 149:337-340
Van Arsdale, Anne R; Arend, Rebecca C; Cossio, Maria J et al. (2018) Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Med 7:616-625
Leath 3rd, Charles A; Monk, Bradley J (2018) Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. Gynecol Oncol 150:391-397
Toboni, Michael D; Smith, Haller J; Bae, Sejong et al. (2018) Predictors of Unplanned Reoperation for Ovarian Cancer Patients From the National Surgical Quality Improvement Program Database. Int J Gynecol Cancer 28:1427-1431
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2017) Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Res 77:207-218
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295

Showing the most recent 10 out of 52 publications